Search results: “GR”

Biologics represents one of the fastest growing classes of biopharmaceutical molecules today. One of the major bottlenecks in the development…

Monoclonal antibodies (MAbs) represent one of the fastest growing classes of biotherapeutic molecules today. While many technologies exist for generating…

DiscoveRx previously introduced a protein-protein interaction system using enzyme fragment complementation that provides a robust, HTS friendly format for monitoring…

The clinical success of an ever-increasing array of biologics has led to the development of a wide spectrum of immunomodulatory…

Cell-based bioassays often pose a hurdle during a rapidly moving biologics development program. High standards for assay accuracy, precision, reproducibility…

Cell-based bioassays often pose a hurdle during a rapidly moving biologics development program. High standards for assay accuracy, precision, reproducibility…

One of the major bottlenecks in the development of biosimilars is the need for good bioassays to create potency, stability…

Cell-based bioassays often pose a hurdle during a rapidly moving biologics development program. High standards for assay accuracy, precision, reproducibility…

Class I therapeutic antibodies achieve their clinical efficacy not only by binding to their target antigen, but also through Fc…

Following the recent regulatory approvals of a number of checkpoint inhibitor therapeutics, development of a wide array of immunomodulatory therapeutic…

DiscoveRx has pioneered a novel enzyme complementation system to monitor cellular events such as protein translocation, protein interactions, and degradation…

Kinase targets have been extensively studied in biochemical assays using purified protein fragments for the kinase and the substrate. However,…